Market Overview

Impax, Glaxo Terminate Collaboration for IPX066

Share:
Related GSK
EXCLUSIVE: Inovio Plans On Producing Zika Vaccine By Q3 2016, Ready For Phase 1 Study By Q4
Benzinga's M&A Chatter for Thursday January 28, 2015
This Week In Pharma: Questions About Dynavax And Alnylam (Seeking Alpha)

Impax Pharmaceuticals, the brand products division of Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that Impax and GlaxoSmithKline (NYSE: GSK) are terminating their collaboration for the development and commercialization of IPX066 outside the United States (U.S.) and Taiwan. IPX066 (known as RYTARY™ in the U.S.) is an investigational extended-release capsule formulation of carbidopa-levodopa being developed for the symptomatic treatment of adult patients with idiopathic Parkinson's disease and is not approved anywhere in the world.

Under the terms of the agreement entered into in December 2010, GSK's right to develop and commercialize IPX066 outside the U.S. and Taiwan will transfer back to Impax effective at the end of July 2013. The decision has been reached because of delays in the anticipated regulatory approval and launch dates in countries in which GSK has rights to commercialize the product.

Impax intends to initiate activities to find a partner or partners for markets outside the U.S. looking to grow their non-US neurology franchise.

Posted-In: News

 

Related Articles (IPXL + GSK)

View Comments and Join the Discussion!

Get Benzinga's Newsletters